Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration

NCT04331730 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT04331730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04331730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 28, 2020
Completion date
September 16, 2021
Enrollment
107 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration